相关实验视频
Updated: May 21, 2025

Scaled-Up Preparation of an Intermediate of Upatinib, ACT051-3
Published on: April 7, 2023
在克罗恩氏病中抗瘤坏死因子-反射性食道病变成功用乌帕达西提尼布治疗
Naohiro Nakamura1, Yusuke Honzawa1, Yuka Ito1
1Third Department of Internal Medicine, Division of Gastroenterology and Hepatology, Kansai Medical University, Hirakata, Japan.
这一案例研究突出了upadacitinib的重要性.
科学领域:
- 胃肠道学和免疫学
- 药物疗效研究 药物疗效研究
- 临床病例报告 临床病例报告
背景情况:
- 克罗恩氏病 (CD) 管理通常涉及免疫抑制剂,如6-美卡波氨酸和抗瘤坏死因子 (anti-TNF) 药物.
- 在CD中,耐火性食道干涉构成了重大的治疗挑战.
- 在复杂的CD病例中,标准治疗可能会失败.
研究的目的:
- 报告使用upadacitinib的第一个成功治疗耐火性食道病变的病例,该病例发生在患有胆管结肠类克罗恩病的患者身上.
- 评估upadacitinib在治疗克罗恩病严重食道表现的疗效.
主要方法:
- 一名39岁的男性患有5年伊利欧结肠性克罗恩病史,接受了6 - 默卡普托普林和阿达利穆马布的治疗.
- 计算机断层扫描和食道胃二透视检查显示食道壁加厚和纵向.
- 患者接受了infliximab,但病变进展,导致开始服用upadacitinib.
- 通过临床评估和生物标志物分析来评估治疗反应.
主要成果:
- 乌帕达西尼布治疗导致所有食道病变的完全愈合.
- 与克罗恩病相关的血清生物标志物在治疗后恢复到负值.
- 患者经历了症状的消失,包括持续的咳.
结论:
- 乌帕达西替尼在克罗恩病中治疗耐火食道病变方面表现出显著的疗效.
- 这对患有克罗恩病严重,耐治疗的食道表现的患者来说是一个新的治疗选择.
- 需要进一步的研究来证实这些发现在更大的患者队列中.
更多相关视频
09:11Y-90 Radioembolization and PD-1 Inhibitor as Neoadjuvant Treatment in Hepatocellular Carcinoma
Published on: May 24, 2024
07:38Multimodal Quantitative Phase Imaging with Digital Holographic Microscopy Accurately Assesses Intestinal Inflammation and Epithelial Wound Healing
Published on: September 13, 2016
相关概念视频
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Peptic Ulcer Disease IV: Management
The therapeutic approach involves ensuring adequate rest, implementing drug therapy, promoting smoking cessation, making dietary modifications, and emphasizing long-term follow-up care.
Pharmacological management
The prevailing therapy for peptic ulcers involves a combination of managing the patient's current...
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
Drugs for Treatment of Ulcerative Colitis in IBD